Myeloproliferative Neoplasms Clinical Trial

A Study of Oral TP-3654 in Patients With Myelofibrosis

Summary

This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of TP-3654 in patients with intermediate or high-risk primary or secondary MF.

View Full Description

Full Description

Arm 1 will enroll patients who have been previously treated and failed on a JAK inhibitor or ineligible to receive ruxolitinib or fedratinib.

Arm 2 will enroll patients who are on a stable dose of ruxolitinib, but who have either lost response or had a suboptimal or plateau in response.

Arm 3 will enroll patients who have been previously treated on JAK inhibitor (except momelotinib) that was complicated by anemia, thrombocytopenia or hematoma.

View Eligibility Criteria

Eligibility Criteria

Patients must meet all of the following inclusion criteria to be eligible:

TP-3654 Monotherapy Arm:

Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET- MF as per WHO diagnostic criteria and intermediate or high-risk primary or secondary MF based on the Dynamic International Prognostic Scoring System (DIPSS)
Previously treated with JAK inhibitor(s) and is intolerant, resistant, refractory or has lost response to the JAK inhibitor(s) or is ineligible to be treated with JAK inhibitor.

Fulfill the following laboratory parameters:

Platelet count ≥ 25 X 10^9 /L, without the assistance of growth factors or platelet transfusions
Absolute Neutrophil Count (ANC) ≥ 1 x 10^9/L without the assistance of granulocyte growth factors
Peripheral blood blast count < 5%
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
Life expectancy ≥ 6 months
Adequate renal function, as determined by clinical laboratory tests (serum creatinine ≤ 1.5 x upper limit of normal (ULN), or calculated creatinine clearance ≥ 30 mL/min) (Cockcroft-Gault)
Adequate hepatic function: ALT and AST ≤ 3 × ULN (ALT and AST ≤ 5 × ULN if liver involvement secondary to MF); direct bilirubin ≤ 2 × ULN
Adequate coagulation function: PT and PTT ≤ 1.5 × ULN; INR ≤ 1.2 × ULN (INR < 2.5 x ULN permitted if on chronic anticoagulant therapy)
Splenomegaly defined as splenic length ≥ 5 cm below the costal margin by palpation or spleen volume of ≥ 450 cm3 by Magnetic Resonance Imaging (MRI) or Computerized Tomography (CT) scan, within 2 weeks prior to Cycle 1 Day 1.
Dose escalation: At least 2 symptoms measurable (score ≥ 1) using the MF-SAF, v4.0.
Dose expansion: At least 2 symptoms measureable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF, v4.0.

TP-3654 + Ruxolitinib Arm:

Confirmed pathological diagnosis of PMF or post-PV-MF/post ET- MF as per WHO diagnostic criteria, and intermediate or high-risk primary or secondary MF based on the DIPSS
Has been on ruxolitinib treatment for ≥ 6 months, and on a stable dose of ruxolitinib (5 to 25 mg BID) for ≥ 8 weeks prior to the first dose of TP-3654, but has either lost response or had a suboptimal or plateau in response

Fulfills the following laboratory parameters:

Platelet count ≥ 50 × 10^9/L (without the assistance of growth factors or platelet transfusions)
ANC ≥ 1 × 109/L without the assistance of granulocyte growth factors
Peripheral blood blast count < 5% at screening
Adequate renal function, as determined by clinical laboratory tests: serum creatinine ≤ 1.5 × ULN or calculated creatinine clearance ≥ 30 mL/min (using Cockcroft-Gault formula)
Adequate hepatic function: ALT and AST ≤ 3 × ULN (ALT and AST ≤ 5 × ULN if liver involvement secondary to MF); direct bilirubin ≤ 2 × ULN
Adequate coagulation function: PT and PTT ≤ 1.5 × ULN; INR ≤ 1.2 × ULN (INR < 2.5 x ULN permitted if on chronic anticoagulant therapy)
Splenomegaly, defined as splenic length ≥ 5 cm below the costal margin by palpation or spleen volume of ≥ 450 cm3 by MRI/CT scan, within 2 weeks prior to Cycle 1 Day 1
At least 2 symptoms measurable with each score ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
ECOG performance status ≤ 1
Life expectancy ≥ 6 months

TP-3654 + Momelotinib Arm

Confirmed pathological diagnosis of PMF or post-PV-MF/post ET-MF as per WHO diagnostic criteria, and intermediate or high-risk primary or secondary MF based on the DIPSS
Previously treated with an approved JAK inhibitor (except momelotinib) for PMF or Post-PV/ET MF for ≥ 12 weeks, or ≥ 4 weeks if JAK inhibitor therapy was complicated by a transfusion requirement of ≥ 4 units of red blood cells in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma
Fulfills the following laboratory parameters:
Anemic, defined as Hb <10 g/dL or requiring RBC transfusion at baseline
Platelet count ≥ 50 × 109/L (without the assistance of growth factors or platelet transfusions)
ANC ≥ 1 × 109/L without the assistance of granulocyte growth factors
Peripheral blood blast count < 5% at screening

Adequate renal function, as determined by clinical laboratory tests: serum creatinine ≤ 1.5 × ULN or calculated creatinine clearance ≥ 30 mL/min (using Cockcroft-Gault formula)

Adequate hepatic function: ALT and AST ≤ 3 × ULN (ALT and AST ≤ 5 × ULN if there is liver involvement secondary to MF); direct bilirubin ≤ 2 × ULN
Adequate coagulation function: PT and PTT ≤ 1.5 × ULN; INR ≤ 1.2 × ULN (INR < 2.5 × ULN permitted if on chronic anticoagulant therapy)
Splenomegaly, defined as splenic length ≥ 5 cm below the costal margin by palpation or spleen volume of ≥ 450 cm3 by MRI/CT scan within 2 weeks prior to Cycle 1 Day 1
At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
ECOG performance status ≤ 1
Life expectancy ≥ 6 months

Patients meeting any one of these exclusion criteria will be prohibited from participating in this study:

TP-3654 Monotherapy Arm:

Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1.
Major surgery within 2 weeks before the first dose of either study drug.
Splenic irradiation within 6 months prior to Screening or prior splenectomy.
Prior allogeneic stem cell transplant within the last 6 months.
Eligible for allogeneic bone marrow or stem cell transplantation.
Unresolved Grade ≥ 2 non-hematological toxicity related to prior treatment
History of symptomatic congestive heart failure, or myocardial infarction, or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; left ventricular ejection fraction (LVEF)< 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1.
Corrected QT interval (using Fridericia's correction formula) of > 480 msec.
Prior or concurrent malignancy whose natural history or treatment would have a significant potential to interfere with the safety or efficacy assessments of the investigational regime.
Known history of chronic liver disease, e.g. portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc.
Experienced portal hypertension or any of its complications.
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic antimicrobial within 1 week prior to Cycle 1 Day 1.
Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
Exhibited allergic reactions or sensitivity to TP-3654, or any structurally similar compound, biological agent, or to any component of the formulation.
Medical condition or gastrointestinal (GI) tract surgery that could impair absorption or result in short bowel syndrome with diarrhea.
Used hydroxyurea or anagrelide within 24 hours prior to the first dose.
Systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to the first dose of study treatment (note: topical, inhaled, nasal, and ophthalmic steroids are not prohibited).

TP-3654 + Ruxolitinib Arm:

Received previous systemic antineoplastic therapy (other than ruxolitinib) or any other experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Note: Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited)
Currently receiving treatment with a prohibited medication that cannot be discontinued at least 1 week prior to Cycle 1 Day 1 (Section 6.9.1)
Known allergic reactions or sensitivity to TP-3654, any structurally similar drug, or to any component of the formulation
Splenic irradiation within 6 months prior to Screening or prior splenectomy
Prior allogeneic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible._
Major surgery within 2 weeks prior to Cycle 1 Day 1
Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed).
Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
Corrected QTcF of > 480 msec
Prior or concurrent malignancy whose natural history or treatment has a significant potential to interfere with the safety or efficacy assessment of the study intervention
History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding

TP-3654 + Momelotinib Arm:

Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Notes: Prior treatment with momelotinib is not allowed, in patients with ongoing JAK inhibitor therapy, ie, ruxolitinib, at screening, JAK inhibitor therapy must be tapered over a period of at least 1 week. Patients on a low dose of ruxolitinib (eg, 5 mg QD) may have a reduced taper period or no taper, hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
Currently receiving treatment with a prohibited medication that cannot be discontinued at least 1 week prior to Cycle 1 Day 1
Known allergic reactions or sensitivity to TP-3654, momelotinib, or any structurally similar drug, or to any component of the formulations of either study intervention
Splenic irradiation within 6 months prior to screening or prior splenectomy
Prior allogenic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible).
Major surgery within 2 weeks prior to Cycle 1 Day 1
Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed)
Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
Presence of Grade ≥ 2 peripheral neuropathy
History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
Corrected QTcF of > 480 msec
Prior or concurrent malignancy whose natural history or treatment has a significant potential to interfere with the safety or efficacy assessment of the study intervention
History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding

Study is for people with:

Myeloproliferative Neoplasms

Phase:

Phase 1

Estimated Enrollment:

240

Study ID:

NCT04176198

Recruitment Status:

Recruiting

Sponsor:

Sumitomo Pharma America, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 35 Locations for this study

See Locations Near You

University of Alabama
Birmingham Alabama, 35294, United States More Info
Tiffany Hill
Contact
205-934-9591
The University of Arizona Cancer Center
Tucson Arizona, 85724, United States More Info
Audrey Johnson
Contact
520-694-9084
[email protected]
City of Hope
Duarte California, 91010, United States More Info
Michelle Velasquez
Contact
626-218-3524
[email protected]
University of Southern California
Los Angeles California, 90033, United States More Info
Shirley Sian
Contact
323-865-0456
[email protected]
Hoag Family Cancer Institute
Newport Beach California, 92663, United States More Info
SMPA Investigative Site
Contact
Blood Cancer Center
Denver Colorado, 80218, United States More Info
Brooke Rhodes
Contact
[email protected]
University of Florida Health Shands Cancer Hospital
Gainesville Florida, 32608, United States
University of Miami
Miami Florida, 33136, United States More Info
Alessia Zoso
Contact
305-243-0327
[email protected]
Emory University
Atlanta Georgia, 30322, United States More Info
SMPA Investigative Site
Contact
University of Chicago
Chicago Illinois, 60637, United States More Info
Howie Weiner
Contact
[email protected]
University of Michigan
Ann Arbor Michigan, 48109, United States More Info
Kelsey Bolin
Contact
734-936-2193
[email protected]
Washington University of Medicine
Saint Louis Missouri, 63110, United States More Info
Nicole Gaudin
Contact
314-747-7960
[email protected]
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack New Jersey, 07601, United States More Info
Jason Brecher
Contact
551-966-5274
[email protected]
Roswell Park Comprehensive Cancer Center
Buffalo New York, 14263, United States
Icahn School of Medicine at Mount Sinai
New York New York, 10029, United States More Info
Mikaela Dougherty
Contact
[email protected]
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States More Info
SMPA Investigative Site
Contact
Weill Cornell Medical Center
New York New York, 10065, United States More Info
Penina Steward
Contact
212-746-1858
[email protected]
Duke Cancer Institute
Durham North Carolina, 27710, United States More Info
Ben Dosan
Contact
[email protected]
Ohio State University
Columbus Ohio, 43210, United States More Info
Molly Brandenburg
Contact
614-366-7951
[email protected]
Tri-Star Centennial Medical Center
Nashville Tennessee, 37203, United States More Info
Brooke Rhodes
Contact
[email protected]
Vanderbilt University
Nashville Tennessee, 37232, United States More Info
SMPA Investigative Site
Contact
MD Anderson Cancer Center
Houston Texas, 77054, United States More Info
Kurt Schroeder
Contact
713-745-2232
[email protected]
Huntsman Cancer Institute
Salt Lake City Utah, 84112, United States More Info
Emerson Lebleu
Contact
801-587-9703
University of Virginia Cancer Center
Charlottesville Virginia, 22903, United States More Info
Kelly Reed
Contact
434-297-7783
[email protected]
University of Washington - Fred Hutchinson Cancer Center
Seattle Washington, 98109, United States More Info
Anna Halpern
Contact
[email protected]
Royal Adelaide Hospital
Adelaide South Australia, , Australia More Info
Christine Hoare
Contact
[email protected]
Eastern Health Box Hill Hospital
Box Hill Victoria, , Australia More Info
SMPA Investigative Site
Contact
Icon Cancer Centre (Ashford Cancer Centre Research)
Adelaide , , Australia More Info
Stanley Cheung, MD
Contact
[email protected]
University Hospitals Leuven
Leuven Vlaams-Brabant, 3000, Belgium More Info
SMPA Investigative Site
Contact
ZNA Cadix
Antwerp , 2020, Belgium More Info
SMPA Investigative Site
Contact
ZNA Middelheim
Antwerp , 2030, Belgium More Info
SMPA Investigative Site
Contact
Centre Hospitalier Universitaire D'Amiens
Amiens , 80054, France More Info
SMPA Investigative Site
Contact
Hospitalier Universitaire (CHU) de Nice - Hopital de l'Archet
Nice , 06200, France More Info
SMPA Investigative Site
Contact
Hospital Saint Louis
Paris , 75010, France More Info
SMPA Investigative Site
Contact
Institut Gustave Roussy
Villejuif , 94805, France More Info
SMPA Investigative Site
Contact
IRCCS Azienda Ospedaliero -Universitaria Di Bologna - Dipartimento Malattie Oncologiche ed Ematologiche - UO Ematologia
Bologna , 40138, Italy More Info
SMPA Investigative Site
Contact
IRCCS istituto Romagnolo per lo studio dei tumori "Dino Amadori"
Meldola , 47014, Italy More Info
SMPA Investigative Site
Contact
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan , 20122, Italy More Info
SMPA Investigative Site
Contact
Azienda Ospedaliera Universitaria Citta' Della Salute E della Scienza di Torino
Torino , 10126, Italy More Info
SMPA Investigative Site
Contact
Aichi Medical University Hospital
Aichi , , Japan More Info
Akiyoshi Takami
Contact
0561-62-3311
[email protected]
National Cancer Center Hospital East
Chiba , , Japan More Info
Junichiro Yuda, MD
Contact
04-7133-1111
[email protected]
Kyushu University Hospital
Fukuoka , , Japan More Info
Takuji Yamauchi, MD
Contact
092-641-1151
[email protected]
University of Miyazaki Hospital
Miyazaki , , Japan More Info
Kazuya Shimoda, MD
Contact
0985-85-1510
[email protected]
Okayama University Hospital
Okayama , , Japan More Info
SMPA Investigative Site
Contact
Osaka University Hospital
Osaka , , Japan More Info
Michiko Ichii, MD
Contact
06-6879-5111
Saitama Medical Center
Saitama , , Japan More Info
Takayuki Tabayashi
Contact
049-228-3411
[email protected]
Tohoku University Hospital
Sendai , , Japan More Info
Yasushi Onishi, MD
Contact
022-717-7000
[email protected]
Shizuoka Cancer Center
Shizuoka , , Japan More Info
Masafumi Fukaya, MD
Contact
055-989-5222
[email protected]
Juntendo University Hospital
Tokyo , , Japan More Info
Shuichi Shirane, MD
Contact
03-3813-3111
[email protected]
United Lincolnshire Hospitals NHS Trust - Pilgrim Hospital
Lincoln , , United Kingdom More Info
SMPA Investigative Site
Contact
University College London Hospital's NHS foundation Trust
London , , United Kingdom More Info
SMPA Investigative Site
Contact

How clear is this clinincal trial information?

Study is for people with:

Myeloproliferative Neoplasms

Phase:

Phase 1

Estimated Enrollment:

240

Study ID:

NCT04176198

Recruitment Status:

Recruiting

Sponsor:


Sumitomo Pharma America, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.